JSKN022 in Subjects With Advanced Malignant Solid Tumors
NCT ID: NCT07292402
Last Updated: 2025-12-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
225 participants
INTERVENTIONAL
2025-10-23
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients to be enrolled are with advanced unresectable or metastatic epithelial-derived malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), or be intolerant to standard treatment, or have no access to standard treatment.
The primary objective of the study is to evaluate the safety and tolerability of JSKN022 in patients with advanced malignant solid tumors and to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of JSKN022.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose escalation cohorts 1
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose escalation cohort 2
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose escalation cohort 3
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose escalation cohort 4
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose escalation cohort 5
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose escalation cohort 6
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose escalation cohort 7
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose escalation cohort 8
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose optimization cohort in selected tumor type 1
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose optimization cohort in selected tumor type 2
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Dose optimization cohort 3 - other advanced epithelial malignant tumors cohort
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JSKN022
JSKN022 administered intravenously at selected dose levels according to protocol
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥ 18 years old, male or female.
3. Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
4. Expected survival ≥ 3 months.
5. Histologically or cytologically confirmed malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), are intolerant to standard treatment, or have no access to standard treatment.
6. At least one measurable lesion at baseline according to RECIST 1.1 criteria.
7. Adequate organ function.
8. Agree to provide Recently archived or fresh tumor tissue samples.
9. Female subjects of childbearing potential or male subjects whose partners are of childbearing potential agree to use effective contraceptive measures.
10. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose.
11. Be able and willing to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol.
12. Adequate washout period of previous therapy before the first dose.
Exclusion Criteria
2. History of brainstem, meningeal metastasis, spinal cord metastasis or compression, or carcinomatous meningitis; presence of active brain metastasis.
3. Screening imaging shows tumor invasion, compression, or occurrence in surrounding important organs or risk of esophagotracheal fistula or esophagopleural fistula, except those judged by the investigator and medical monitor to not affect the patient's enrollment and administration.
4. Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
5. Presence of the risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia:
6. Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
7. Gastrointestinal abnormalities with obvious clinical manifestations.
8. Active autoimmune diseases requiring systemic treatment within the past two years.
9. Significant serous effusion.
10. Uncontrolled infection.
11. Require regular glucocorticoid or immunosuppressive therapy.
12. Received live vaccines within 28 days before the first dose, or plan to receive live vaccines during the study period.
13. Prior treatment with antibody-drug conjugates containing topoisomerase I inhibitors.
14. Previous occurrence of grade ≥ 3 immune-related adverse events during immunotherapy.
15. Toxicity of previous anti-tumor treatment has not fully or partially recovered.
16. Known allergy to any component of the study drug, or history of severe allergic reactions to other antibody drugs.
17. Pregnant and/or lactating women, or planning to become pregnant during the study period.
18. Known history of mental illness, substance abuse, alcoholism, etc., or other situations that the investigator deems may affect the safety or compliance of the study drug treatment.
19. Local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which may lead to high medical risks and/or uncertainty in survival assessment, such as tumor-related leukemia reaction (white blood cell count \> 20×10⁹/L), cachexia manifestations, etc.
20. Any other previous or current diseases, treatments, or laboratory test abnormalities that the investigator deems may confuse the study results, affect the patient's full participation in the study, or participation in the study may not be in the best interest of the patient.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ruihua Xu, Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JSKN022-101
Identifier Type: -
Identifier Source: org_study_id